

# 4<sup>th</sup> International Pharma & Clinical Pharmacy Congress

November 07-09, 2016 Las Vegas, Nevada, USA

Cost-effectiveness analysis of additional Bevacizumab to chemotherapy for malignant pleural mesothelioma from a Chinese perspective

Mei Zhan  
West China Hospital, China

**Objective:**To evaluate the cost-effectiveness of addition of bevacizumab to pemetrexed plus cisplatin (PC) for malignant pleural mesothelioma (MPM) following a phase III trial that show an overall survival (OS) benefit with the addition of bevacizumab.

**Methods:**A Markov decision tree based on the mesothelioma avastin cisplatin pemetrexed study (MAPS) was created, comparing bevacizumab+PC to PC alone. Three health states (progression-free survival, progressive disease and death) were analyzed in a Markov model. The costs were calculated from the Chinese societal perspective. Results were reported in quality-adjusted life year (QALY) and incremental cost-effectiveness ratios (ICERs).

**Results:**Bevacizumab+PC came at an ICER of \$323343.46 per QALY, which are much more than the accepted willingness-to-pay (WTP) threshold of \$23970.00 per QALY in China.

**Conclusions:**

Notes: